Arcus Biosciences (NYSE:RCUS) Price Target Cut to $18.00 by Analysts at HC Wainwright

Arcus Biosciences (NYSE:RCUS) had its price objective lowered by HC Wainwright from $20.00 to $18.00 in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the stock. HC Wainwright also issued estimates for Arcus Biosciences’ Q1 2025 earnings at ($1.30) EPS, Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.15) EPS and FY2029 earnings at ($1.80) EPS.

A number of other analysts have also weighed in on the company. Barclays increased their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Arcus Biosciences Stock Down 3.1 %

Shares of NYSE RCUS opened at $10.76 on Tuesday. Arcus Biosciences has a one year low of $10.63 and a one year high of $20.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm’s 50 day simple moving average is $14.02 and its two-hundred day simple moving average is $15.56. The stock has a market capitalization of $984.21 million, a P/E ratio of -3.41 and a beta of 0.84.

Insider Buying and Selling

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares of the company’s stock, valued at $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 12.30% of the stock is currently owned by insiders.

Institutional Trading of Arcus Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. R Squared Ltd purchased a new position in Arcus Biosciences during the fourth quarter valued at $26,000. Point72 Hong Kong Ltd purchased a new position in Arcus Biosciences during the third quarter valued at $47,000. Lazard Asset Management LLC lifted its position in Arcus Biosciences by 3,321.3% during the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after buying an additional 6,078 shares during the period. US Bancorp DE lifted its position in Arcus Biosciences by 2,432.0% during the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after buying an additional 6,615 shares during the period. Finally, Quest Partners LLC lifted its position in Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.